Defining a novel law of glucose homeostasis under Dapagliflozin usage by mathematical model approach
Not Applicable
- Conditions
- diabetes mellitus
- Registration Number
- JPRN-UMIN000019476
- Lead Sponsor
- Division of Diabetes and Endocrinology Department of Internal Medicine,Kobe University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) pregnant or breast-feeding women 2) insulin antibody positive (>10 arbitrary unit) 3) having allergy or skin trouble for oral hypoglycemic agants or insulin 4) type 1 diabetes or other specific type of diabetes 5) severe liver dysfunction (transaminase twice over the normal limit) 6) severe renal dysfunction (eGFR < 50) 7) severe heart failure (NYHA>2) 8) long-acting insulin, long-acting GLP-1 RA, or long-acting DPP-4 inhibitor user 9) psychological disorder 10) recent severe hypoglycemia or hypoglycemia unawareness 11) contraindication of dapagliflozine 11) others inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method